Analysts Offer Insights on Healthcare Companies: Amgen Inc (HTGM), Intercept Pharma (ICPT) and HTG Molecular Diagnostics (HTGM)


There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Amgen Inc (NASDAQ: AMGN), Intercept Pharma (NASDAQ: ICPT) and HTG Molecular Diagnostics (NASDAQ: HTGM) with bullish sentiments.

Amgen Inc (NASDAQ: AMGN)

In a report released today, Leah R. Cann from Oppenheimer maintained a Buy rating on Amgen Inc (NASDAQ: AMGN), with a price target of $224. The company’s shares opened today at $183.89.

Cann observed:

“The timing of this EC approval of Prolia in GIOP is in line with our expectations, following FDA approval in this setting in May 2018. in GIOP in the EU supports our expectations for Prolia sales through 2022. With this approval, patients who receive treatment with glucocorticoids, who need options to improve their bone mineral density, provide a new addressable market for Prolia. Prolia is in its eighth year of launch, and has achieved an estimated market penetration of greater than 60%. We anticipate Prolia sales will increase to $2.75 billion in 2022 from $1.97 billion in 2017 and will account for 8.4% of sales.”

According to TipRanks.com, Cann is a 5-star analyst with an average return of 23.3% and a 59.6% success rate. Cann covers the Healthcare sector, focusing on stocks such as Miragen Therapeutics Inc, CytomX Therapeutics Inc, and Crispr Therapeutics AG.

Currently, the analyst consensus on Amgen Inc is Strong Buy and the average price target is $197.63, representing a 7.5% upside.

In a report issued on June 5, Mizuho Securities also maintained a Buy rating on the stock with a $200 price target.

See today’s analyst top recommended stocks >>

Intercept Pharma (NASDAQ: ICPT)

In a report released today, Liana Moussatos from Wedbush maintained a Buy rating on Intercept Pharma (NASDAQ: ICPT), with a price target of $203. The company’s shares opened today at $71.89.

According to TipRanks.com, Moussatos is a 4-star analyst with an average return of 9.4% and a 44.4% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Allena Pharmaceuticals Inc, Global Blood Therapeutics, and Catabasis Pharmaceuticals.

Intercept Pharma has an analyst consensus of Moderate Buy, with a price target consensus of $121.

HTG Molecular Diagnostics (NASDAQ: HTGM)

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on HTG Molecular Diagnostics (NASDAQ: HTGM) today and set a price target of $7. The company’s shares opened today at $3.93.

According to TipRanks.com, Selvaraju is a 2-star analyst with an average return of 0.8% and a 41.6% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, Biospecifics Technologies Corp, and EyePoint Pharmaceuticals Inc.

HTG Molecular Diagnostics has an analyst consensus of Moderate Buy, with a price target consensus of $7.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts